The Alternative to Foam Negative Pressure Wound Therapy Is Cleared by the FDA

Boston, Massachusetts--(Newsfile Corp. - September 23, 2022) - Applied Tissue Technologies (ATT), an advanced wound care company, announced the 510k clearance by the FDA today of its Platform Wound Dressing "PWD(R)" Negative Pressure Wound Therapy "NPWT" System. This clearance pairs ATT's revolutionary embossed dressing with a purpose built pump developed from the ground up for use with this dressing.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Eliminating Foam and Gauze Wound Fillers in Negative Pressure Wound Therapy Dressings Simplifies Treatment and avoids complications related to foam and gauze.
  • Published GLP Preclinical study demonstrates PWD's advantages against market leaders.
  • Clinical Safety study has been completed.

Cannot view this image? Visit:

Click image above to view full announcement.

The PWD is a member ATT's globally patented portfolio of advanced wound care products including, the Xpansion(R) MicroAutografting Kit and establishes a product line of advanced wound care technologies that can reestablish the skin barrier function, deliver topical therapeutics and close wounds with the gold standard of wound healing, an autologous split thickness skin graft.

Applied Tissue Technologies brings advancements in wound healing to patients. This includes research and development supported by the United States Department of Defense to help wounded warriors at the point of injury, instances of prolonged field care and delayed evacuation, and also continuing through advanced levels of military medical care.    @npwtsimplified

The PWD is supported in part by the United States Defense Health Agency (Small Business Innovation Research) contract number W81XWH-14-C-0015, USAMRAA, and USAMRMC through contract numbers W81XWH-18-2-0002, W81XWH-18-C-0143, W81XWH-19-2-0038 and W81XWH-16-0784. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.


Michael Broomhead

Source: Applied Tissue Technologies

To view the source version of this press release, please visit